Mirum Pharmaceuticals Inc (MIRM) Stock Price, Quote & News

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 667 4085

Website: www.mirumpharma.com

Address:

950 Tower Lane, Suite 1050, Foster City, United States

valueforme Aug. 4 at 3:59 AM

$MIRM Based on examples I researched generic companies tend to file ANDA and challenge patents of successful smid cap commercial bios around 4 years after approvals. It will soon be be 4 years since Livmarli initial approval . News like ANDA filing by generic folks do usually lead to a temporary drop of 25% or so. I'm not saying this is going to happen here, but there is a chance of sub $40 in 2025 on such news , which would be a good opportunity to buy

0 · Reply

Doozio Aug. 2 at 1:59 PM

$MIRM out of the tightness with huckleberries ready TTWO ASND thru $$$$ patterns 🐒🍌🧠⏰♾️

0 · Reply

LMXPERTEN Jul. 30 at 12:13 PM

$MIRM Premarket 😅

0 · Reply

LMXPERTEN Jul. 23 at 4:36 PM

$BBIO $MIRM 😎

0 · Reply

ZacksResearch Jul. 17 at 3:46 PM

$MIRM up 35% in 3 months — time to chase or take profits? Livmarli sales are soaring and bile acid product demand is ramping up fast — fueling the breakout. Full setup breakdown here 👉 https://www.zacks.com/stock/news/2588627/mirum-gains-35-in-3-months-how-should-you-play-the-stock?cid=sm-stocktwits-2-2588627-teaser-2352&ADID=SYND_STOCKTWITS_TWEET_2_2588627_TEASER_2352

0 · Reply

ZacksResearch Jul. 17 at 2:23 PM

$MIRM soars 35% in 3 months — what's fueling the rally? 🚀 Livmarli's net product sales surged 71% to $73.2M in Q1 2025, driving strong performance and raising 2025 revenue guidance to $435-$450M. However, competition from rivals like Ipsen looms large. See why staying invested might be wise 👉 https://www.zacks.com/stock/news/2588627/mirum-gains-35-in-3-months-how-should-you-play-the-stock?cid=sm-stocktwits-2-2588627-body-2295&ADID=SYND_STOCKTWITS_TWEET_2_2588627_BODY_2295

0 · Reply

jb02345 Jul. 15 at 7:50 PM

$MIRM tried to buy some puts. Nothing available. Hopefully a BO

0 · Reply

LMXPERTEN Jul. 14 at 6:18 PM

$MIRM who cares? Just an ATH 😅😂

0 · Reply

davirom Jul. 11 at 6:16 PM

$MIRM Almost a year has passed since the rumour about the buyout by Swedish Orphan Biovitrum AB. Back then, I would have been happy to sell at 70. With the developments since last year, 80$ would be a decent price.

0 · Reply

Doozio Jul. 9 at 7:49 PM

$MIRM 🐒🍌🧠⏰♾️ is whuts NXT!

0 · Reply

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jul 10, 2025, 6:15 PM EDT - 25 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2025, 8:30 AM EDT - 2 months ago

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 14, 2025, 4:05 PM EDT - 2 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 9, 2025, 8:30 AM EDT - 3 months ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 7, 2025, 9:17 PM EDT - 3 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 3 months ago

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 6:45 PM EDT - 3 months ago

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

Apr 30, 2025, 8:30 AM EDT - 3 months ago

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 28, 2025, 8:30 AM EDT - 3 months ago

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Apr 14, 2025, 8:30 AM EDT - 4 months ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Mar 27, 2025, 8:30 AM EDT - 4 months ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 24, 2025, 5:17 PM EDT - 4 months ago

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Feb 27, 2025, 7:10 AM EST - 5 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 5 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:30 AM EST - 5 months ago

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Feb 21, 2025, 12:01 PM EST - 5 months ago

US FDA approves Mirum Pharma's genetic disorder drug

Feb 19, 2025, 4:04 PM EST - 5 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Jan 13, 2025, 8:30 AM EST - 7 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 8, 2025, 11:05 AM EST - 7 months ago

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 6, 2025, 4:04 PM EST - 7 months ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 25, 2024, 10:00 AM EST - 7 months ago

Mirum Pharma: Buy At Dips For Volixibat Potential

Nov 14, 2024, 8:00 AM EST - 9 months ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Nov 12, 2024, 1:51 PM EST - 9 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:00 AM EST - 9 months ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 9 months ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 9 months ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Oct 10, 2024, 8:30 AM EDT - 10 months ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Aug 9, 2024, 9:10 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Jul 17, 2024, 3:48 AM EDT - 1 year ago

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 8, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Jun 27, 2024, 4:48 PM EDT - 1 year ago

3 Biotech Stocks For The Second Half Of 2024

ALT NTLA

Jun 17, 2024, 10:53 AM EDT - 1 year ago

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Jun 16, 2024, 5:00 PM EDT - 1 year ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 31, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 29, 2024, 8:30 AM EDT - 1 year ago

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 18, 2024, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 11, 2024, 2:25 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:10 PM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

FSV

May 1, 2024, 4:10 PM EDT - 1 year ago

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Apr 22, 2024, 3:04 PM EDT - 1 year ago

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

valueforme Aug. 4 at 3:59 AM

0 · Reply

Doozio Aug. 2 at 1:59 PM

$MIRM out of the tightness with huckleberries ready TTWO ASND thru $$$$ patterns 🐒🍌🧠⏰♾️

0 · Reply

LMXPERTEN Jul. 30 at 12:13 PM

$MIRM Premarket 😅

0 · Reply

LMXPERTEN Jul. 23 at 4:36 PM

$BBIO $MIRM 😎

0 · Reply

ZacksResearch Jul. 17 at 3:46 PM

0 · Reply

ZacksResearch Jul. 17 at 2:23 PM

0 · Reply

jb02345 Jul. 15 at 7:50 PM

$MIRM tried to buy some puts. Nothing available. Hopefully a BO

0 · Reply

LMXPERTEN Jul. 14 at 6:18 PM

$MIRM who cares? Just an ATH 😅😂

0 · Reply

davirom Jul. 11 at 6:16 PM

0 · Reply

Doozio Jul. 9 at 7:49 PM

$MIRM 🐒🍌🧠⏰♾️ is whuts NXT!

0 · Reply

Sillyspuh Jul. 9 at 6:52 PM

$MIRM Nice to see this waking up.

0 · Reply

TrendEdgeLogan Jul. 9 at 5:54 PM

$XBI biotech crushing it in the favorite's list today. $CNTA $AXSM $MIRM $ONC

0 · Reply

LMXPERTEN Jul. 9 at 5:32 PM

$MIRM $ALBO $BBIO you know LMXPERTEN’s best of stocktwits. 🤠

0 · Reply

Home_Skillet Jul. 9 at 4:05 PM

$CAPR here’s some safe ones bro! $MIRM $BBIO $KALV

0 · Reply

TrendEdgeLogan Jul. 8 at 1:52 PM

$MIRM $2.42B mc founder-led, increasingly institutionally owned, and short squeeze name looks ready to rock with a biotech follow through week. High conviction list for me Trendedge.app/asset/MIRM

0 · Reply

AtlantisSwimInstructor Jul. 5 at 4:06 PM

$MIRM 1581

1 · Reply

LMXPERTEN Jun. 27 at 9:46 PM

$MIRM unbelievable. We have a stock moving up up up almost ATH now and no one seems to care. Im loading and loading and loading.

1 · Reply

IOANNISMICHAEL Jun. 27 at 12:52 PM

$MIRM bagholders sitting on 50£ from Feb 26, hope the get out soon to see a new gap up

0 · Reply

LMXPERTEN Jun. 26 at 4:48 PM

$MIRM the forum is as dead as the stock. I told you all about the quiet period. Barely any milestones at all. Nothing to talk about. Hence ready for BO.

0 · Reply

Polip Jun. 17 at 2:39 PM

$DAWN $MIRM $IOVA $GERN are obvious M&A targets. Give it a year and they will not be trading on the Nasdaq exchange.

2 · Reply

LMXPERTEN Jun. 16 at 9:33 PM

$MIRM all my bios green. XBI down. 👑

1 · Reply

LMXPERTEN Jun. 13 at 7:19 PM

$MIRM give us 50

1 · Reply

Market Cap	2.58B
Revenue (ttm)	336.89M
Net Income (ttm)	-87.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26.10%
Debt to Equity Ratio	0.00

Volume	313,500
Avg Vol	402,690
Day's Range	N/A - N/A
Shares Out	49.54M
Stochastic %K	50%
Beta	0.94
Analysts	Strong Sell
Price Target	$68.30